Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Q Sun, Z Hong, C Zhang, L Wang, Z Han… - Signal transduction and …, 2023 - nature.com
Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …
Non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is
responsible for the majority of cancer-related deaths worldwide. The management of …
responsible for the majority of cancer-related deaths worldwide. The management of …
Rare molecular subtypes of lung cancer
Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
I Otano, AC Ucero, J Zugazagoitia… - Nature reviews Clinical …, 2023 - nature.com
Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
I Mota, E Patrucco, C Mastini, NR Mahadevan, TC Thai… - Nature Cancer, 2023 - nature.com
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …
treated with ALK tyrosine kinase inhibitors (TKIs), but the lack of activity of immune …
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to
immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying …
immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying …
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint
blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L) 1 …
blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L) 1 …
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
C Liu, S Zheng, Z Wang, S Wang, X Wang… - Cancer …, 2022 - Wiley Online Library
Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …